Evidence map›Paper›PMID 27143853›Full record

ArticleDrug design, development and therapy2016

Neuroprotective effect of β-asarone against Alzheimer's disease: regulation of synaptic plasticity by increased expression of SYP and GluR1.

Si-Jun Liu, Cong Yang, Yue Zhang, Ru-Yu Su, Jun-Li Chen, Meng-Meng Jiao, Hui-Fang Chen, Na Zheng, Si Luo, Yun-Bo Chen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
10.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Volatile oil ofFrontiers in pharmacology · 2025
    Review
  6. IGF-1's protective effect on OSAS rats' learning and memory.Sleep & breathing = Schlaf & Atmung · 2024
    Article
  7. Article
  8. New Value ofNutrients · 2024
    Article
  9. Review
  10. Article
  11. Therapeutic Potential of Active Components fromJournal of pharmacopuncture · 2022
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Role of Vacha (Journal of clinical medicine · 2020
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Si-Jun LiuSchool of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Cong YangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Yue ZhangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Ru-Yu SuInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Jun-Li ChenInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Meng-Meng JiaoInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Hui-Fang ChenInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Na ZhengInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Si LuoInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Yun-Bo ChenInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Shi-Jian QuanSchool of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Qi WangInstitute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimβ-asarone, an active component of Acori graminei rhizome, has been reported to have neuroprotective effects in Alzheimer's disease. As the underlying mechanism is not known, we investigated the neuroprotective effects of β-asarone in an APP/PS1 double transgenic mouse model and in NG108 cells. MATERIALS AND

methodsAPPswe/PS1dE9 double transgenic male mice were randomly assigned to a model group, β-asarone treatment groups (21.2, 42.4, or 84.8 mg/kg/d), or donepezil treatment group (2 mg/kg/d). Donepezil treatment was a positive control, and background- and age-matched wild-type B6 mice were an external control group. β-asarone (95.6% purity) was dissolved in 0.8% Tween 80 and administered by gavage once daily for 2.5 months. Control and model animals received an equal volume of vehicle. After 2.5 months of treatment, behavior of all animals was evaluated in a Morris water maze. Expression of synaptophysin (SYP) and glutamatergic receptor 1 (G1uR1) in the hippocampus and cortex of the double transgenic mice was assayed by Western blotting. The antagonistic effects of β-asarone against amyloid-β peptide (Aβ) were investigated in vitro in the NG108-15 cell line. After 24 hours of incubation, cells were treated with 10 μm Aβ with or without β-asarone at different concentrations (6.25, 12.5, or 25 μM) for an additional 36 hours. The cytotoxicity of β-asarone was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay of cell viability, and cell morphology was evaluated by bright-field microscopy after 24 hours of treatment. The expression of SYP and GluR1 in cells was detected by Western blot assay in the hippocampus and brain cortex tissues of mice.

resultsβ-asarone at a high dose reduced escape latency and upregulated SYP and GluR1 expression at both medium and high doses. Cell morphology evaluation showed that β-asarone treatment did not result in obvious cell surface spots and cytoplasmic granularity. β-asarone had a dose-dependent effect on cell proliferation.

conclusionβ-asarone antagonized the Aβ neurotoxicity in vivo, improved the learning and memory ability of APP/PS1 mice, and increased the expression of SYP and GluR1 both in vivo and in vitro. Thus, β-asarone may be a potential drug for the treatment of Alzheimer's disease.

Indexed as

Allylbenzene DerivativesAlzheimer DiseaseAnimalsAnisolesCells, CulturedDose-Response Relationship, DrugMaleMaze LearningMiceMice, TransgenicMolecular StructureNeuronal PlasticityNeuroprotective AgentsReceptors, AMPAStructure-Activity RelationshipSynaptophysinAllylbenzene DerivativesAnisolesasaroneNeuroprotective AgentsReceptors, AMPASynaptophysinSyp protein, mouseglutamatergic receptor 1neuroprotective effectsynaptic plasticitysynaptophysinβ-asarone

Identifiers

PMID27143853
PMCPMC4841421
OpenAlexW2336077496

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.